Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart probe could help surgeons remove all cancer in one go

NCT ID NCT05104619

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called SpiderMass that analyzes tissue molecules in real time during tongue cancer surgery. The goal is to help surgeons instantly tell cancerous from healthy tissue, so they can remove all the tumor in one operation. Currently, about 15-30% of patients need additional treatment because cancer cells are found at the surgical edge days later. This trial enrolls 33 adults with squamous cell carcinoma of the tongue who are having surgery as their first treatment. The device is being trained to recognize cancer patterns, which is the first step toward using it as a surgical guide.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SpiderMass spectroscopy probe
What this could lead to
If successful, this technology could help surgeons remove all cancer during one operation, reducing the need for follow-up treatments.
What could go wrong
This is an early learning phase with only 33 participants. The technology must first be trained to distinguish healthy from cancerous tissue, and it may not work in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 33 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2021

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated in the Maxillofacial Surgery Department of the CHU Amiens-Picardie for a squamous cell carcinoma of the tongue and for whom the first-line treatment is surgical resection

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age : 18 years and older * squamous cell carcinoma of the tongue * surgical resection as first-line treatment * tumor classification T1 to T4. Exclusion Criteria: * metastatic disease * neoadjuvant therapies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mass spectroscopy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Margins of Excision squamous cell carcinoma tongue disorder tongue squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mass spectroscopy Molecular profile Oral cavity Squamous cell carcinoma Surgical margins TONGUE

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire d'Amiens

    RECRUITING

    Amiens, Picardie, 80000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.